Publicaciones en las que colabora con Ramón Colomer Bosch (20)

2023

  1. Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement

    eClinicalMedicine, Vol. 60

2022

  1. Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

    Nature Communications, Vol. 13, Núm. 1

2020

  1. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

    Breast Cancer Research, Vol. 22, Núm. 1

2019

  1. Nintedanib plus letrozole in early breast cancer: A phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

    Breast Cancer Research, Vol. 21, Núm. 1

2017

  1. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2008

  1. Factores pronósticos y predictivos

    Tratado de cáncer de mama (You & Us, S.A), pp. 13-24

  2. Novel chemotherapy approaches in chemoradiation protocols

    Gynecologic Oncology, Vol. 110, Núm. 3 SUPPL.2

2006

  1. Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: Efficacy and correlation with HER2 extracellular domain

    Clinical and Translational Oncology, Vol. 8, Núm. 12, pp. 896-902

2005

  1. It is not time to stop progesterone receptor testing in breast cancer [16]

    Journal of Clinical Oncology

2004

  1. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain

    Annals of Oncology, Vol. 15, Núm. 2, pp. 201-206

  2. Initially Metastatic Breast Carcinoma Has a Distinct Disease Pattern but an Equivalent Outcome Compared with Recurrent Metastatic Breast Carcinoma

    Cancer, Vol. 100, Núm. 9, pp. 1833-1842

2003

  1. A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer

    Clinical Breast Cancer, Vol. 4, Núm. 4, pp. 286-291

2002

  1. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: A randomized trial

    Journal of the National Cancer Institute, Vol. 94, Núm. 14, pp. 1054-1065

2001

  1. High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: A phase I trial

    Bone Marrow Transplantation, Vol. 27, Núm. 2, pp. 117-123

  2. High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: A Phase II multicentric trial

    Cancer, Vol. 92, Núm. 10, pp. 2508-2516

1999

  1. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: A prospective, randomized clinical trial

    Cancer, Vol. 85, Núm. 1, pp. 213-219

1997

  1. Patient selection in high-dose chemotherapy trials: Relevance in high- risk breast cancer

    Journal of Clinical Oncology, Vol. 15, Núm. 10, pp. 3178-3184

  2. Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer

    Seminars in Oncology, Vol. 24, Núm. 6 SUPPL. 19

  3. Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancer

    Seminars in Oncology

1995

  1. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: Preliminary results

    Seminars in Oncology, Vol. 22, Núm. 6 SUPPL. 15, pp. 50-54